31 active shortage notices across 6 countries · 1 anticipated.
Last updated 17 Sept 2026 · sourced from official medicines regulators
| Country | Severity | Notices | Since | Est. resolution | Source |
|---|---|---|---|---|---|
| United States | high | 3 | 29 May 2013 | — | FDA MedWatch |
| New Zealand |
| high |
| 1 |
| 12 May 2026 |
| — |
| Pharmac |
| Canada | medium | 14 | 10 Mar 2017 | 31 Oct 2026 | HC |
| Netherlands | medium | 11 | 19 Feb 2026 | — | CBG-MEB |
| Germany | medium | 1 | 3 Aug 2026 | 6 Oct 2026 | BfArM |
| Australia | medium | 1 | 20 Mar 2026 | 17 Apr 2026 | TGA |
Clinically related options from Mederti's curated alternatives data. Always confirm suitability with a pharmacist or prescriber before substituting.
Yes. As of the latest regulator updates, Naproxen has 31 active shortage notices across 6 countries (United States, New Zealand, Canada, Netherlands, Germany, Australia). Status is refreshed daily from official regulatory sources.
Regulators attribute the current Naproxen shortages to manufacturing problems, causes not stated by the regulator, unexpected increases in demand. The exact cause varies by country and product — each notice on this page links to the official source.
Regulator-estimated resolution dates currently range from 25 Dec 2024 to 31 Oct 2026, depending on country and product. These estimates come from the manufacturers via regulators and often change — check the per-country table above for the latest.
Mederti lists 1 clinically related alternative for Naproxen (see the alternatives section above). Alternatives require clinical judgement — always confirm suitability with a pharmacist or prescriber and your national guidance before substituting.
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ regulators across 50+ countries and never publishes unsourced shortage claims.
Cabergoline · Bromocriptine-Mesilate · Cabergolina · Bromocriptine (Mésilate De) · Cabergolina Teva · Atosiban
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.